<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224844</url>
  </required_header>
  <id_info>
    <org_study_id>AntalyaTRH029</org_study_id>
    <nct_id>NCT04224844</nct_id>
  </id_info>
  <brief_title>Erector Spinae Plane Block for Carotid Endarterectomy</brief_title>
  <official_title>Ultrasound-Guided Spinae Plane Block for Perioperative Pain Control in Carotid Endarterectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antalya Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antalya Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that erector spinae plane block will
      decrease intraoperative local anesthetic and postoperative analgesic consumption in patients
      undergoing carotid endarterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who decided to participate in the study will be randomized into 2 groups: Erector
      Spinae Plane Block Group (Group E) and Control Group (Group C). Intraoperative local
      anesthetic consumption, postoperative tramadol consumption, intraoperative and pain scores,
      hemodynamic parameters and patient satisfaction will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    not recruiting, awaiting for changes in IRB
  </why_stopped>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hours tramadol consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Total tramadol consumption in milligrams at 24 hrs will be scored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 hours tramadol consumption</measure>
    <time_frame>6 hours</time_frame>
    <description>Total tramadol consumption in milligrams at 6 hrs will be scored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 hours tramadol consumption</measure>
    <time_frame>12 hours</time_frame>
    <description>Total tramadol consumption in milligrams at 12 hrs will be scored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assesment of postoperative analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Post operative pain scores will be assessed using a numerical rating scala (NRS) (from 0=no pain, to10= worst pain imaginable) at 24 hrs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assesment of postoperative analgesia</measure>
    <time_frame>6 hours</time_frame>
    <description>Post operative pain scores will be assessed using a numerical rating scala (NRS) (from 0=no pain, to10= worst pain imaginable) at 6 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assesment of postoperative analgesia</measure>
    <time_frame>12 hours</time_frame>
    <description>Post operative pain scores will be assessed using a numerical rating scala (NRS) (from 0=no pain, to10= worst pain imaginable) at 12 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of use of intraoperative local anesthetic.</measure>
    <time_frame>1 hour</time_frame>
    <description>Intraoperative pain will be assessed using a visual analog scale (VAS) (from 0 = no pain to 10 = maximum possible pain). When intraoperative VAS is &gt;3, supplemental local anesthetic will be administered to the surgical area by the surgeon. Amount of total local anesthetic in milligrams will be recorded at the end of the surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Erector spinae plane block group (Group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive erector spinae plane block in addition to intravenous patient-controlled analgesia device containing tramadol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (Group 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group will receive only intravenous patient-controlled analgesia device containing tramadol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Erector spinae plane block</intervention_name>
    <description>The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.</description>
    <arm_group_label>Erector spinae plane block group (Group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.</description>
    <arm_group_label>Control group (Group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing carotid endarterectomy

          -  American Society of Anesthesiologists class 2 to 3

          -  Ability to consent

        Exclusion Criteria:

          -  inability to communicate

          -  not understand the aim and objectives of the study

          -  not provide informed written consent

          -  contraindications for the block (local infection, coagulation disorders)

          -  hypersensitivity to the local anesthetics

          -  refusal of regional anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Sait Kavakli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antalya Training and Reseach Hospital</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

